Compile Data Set for Download or QSAR
maximum 50k data
Found 74 Enz. Inhib. hit(s) with all data for entry = 1314
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316508(2-({(3R,6R)-6-methyl-1-[(3- pyrimidin-2-ylthiophen...)
Affinity DataIC50:  5.30nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316512(Methyl 4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,...)
Affinity DataIC50:  11.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316475(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50:  13.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316484(2-{[(3R,6R)-6-methyl-1-{[3-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50:  14.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316490(2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3- triazol-2-yl)...)
Affinity DataIC50:  14.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316486(2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  15.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316494(2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6- methylpip...)
Affinity DataIC50:  16.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316496(2-({(3R,6R)-1-[(2- cyclopropylphenyl)carbonyl]-6- ...)
Affinity DataIC50:  18.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316510(2-{[(3R,6R)-6-Methyl-1-{[2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50:  18.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316507(2-({(3R,6R)-6-methyl-1-[(2- pyrimidin-2- ylphenyl)...)
Affinity DataIC50:  18.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316506(2-({(3R,6R)-6-Methyl-1-[(2-pyrimidin-2-ylthiophen-...)
Affinity DataIC50:  19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316477(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50:  20nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316485(2-{[(3R,6R)-1-{[3-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  20.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316469(Methyl 4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2...)
Affinity DataIC50:  22.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316472(US9617246, 4 | methyl 4-iodo-2-{[(3R,6R)-6-methyl-...)
Affinity DataIC50:  23.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 3 | US9617246, 48 | methyl 2-{[(3R,6R)-...)
Affinity DataIC50:  23.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316476(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50:  24.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316487(2-{[(3R,6R)-1-{[4-fluoro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  26.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316469(Methyl 4-methyl-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2...)
Affinity DataIC50:  27.8nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316499(2-{[(3R,6R)-6-methyl-1-{[2-(1- methylethoxy)phenyl...)
Affinity DataIC50:  29.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316497(2-{[(3R,6R)-6-methyl-1-{[2-(1-methyl- 1H-pyrazol-4...)
Affinity DataIC50:  30.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316504(2-{[(3R,6R)-6-methyl-1-{[2-(tetrahydro- 2H-pyran-2...)
Affinity DataIC50:  36.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 3 | US9617246, 48 | methyl 2-{[(3R,6R)-...)
Affinity DataIC50:  48.1nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316488(2-{[(3R,6R)-6-methyl-1-{[4-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50:  49nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316483(2-{[(3R,6R)-1-{[2-methoxy-6-(2H-1,2,3- triazol-2-y...)
Affinity DataIC50:  51.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316482(2-{[(3R,6R)-1-{[2-fluoro-6-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  51.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316472(US9617246, 4 | methyl 4-iodo-2-{[(3R,6R)-6-methyl-...)
Affinity DataIC50:  54.4nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316495(2-({(3R,6R)-6-methyl-1-[(2- phenoxyphenyl)carbonyl...)
Affinity DataIC50:  62.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316498(2-({(3R,6R)-6-methyl-1-[(2- phenylpyridin-3-yl)car...)
Affinity DataIC50:  71.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316512(Methyl 4-methoxy-2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,...)
Affinity DataIC50:  73.2nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316500(2-{[(3R,6R)-6-methyl-1-{[2- (methylsulfanyl)phenyl...)
Affinity DataIC50:  75.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316470(2-methyl-6-{[(3R,6R)-6-methyl- 1-{[2-(2H-1,2,3-tri...)
Affinity DataIC50:  82.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316505(2-({(3R,6R)-6-methyl-1-[(2-pyrrolidin-1- ylphenyl)...)
Affinity DataIC50:  103nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316480(2-{[(3R,6R)-1-{[6-Methoxy-2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50:  149nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316473(2-{[(3R,6R)-6-methyl-1-{[2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50:  179nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316491(2-{[(3R,6R)-1-{[5-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  214nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316489(2-{[(3R,6R)-1-{[4-methoxy-2-(2H-1,2,3- triazol-2-y...)
Affinity DataIC50:  224nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316494(2-{[(3R,6R)-1-(biphenyl-2-ylcarbonyl)-6- methylpip...)
Affinity DataIC50:  279nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316479(US9617246, 13 | methyl 2-{[(3R,6R)-6-methyl-1- {[2...)
Affinity DataIC50:  297nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316474(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50:  322nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316477(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50:  440nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316490(2-{[(3R,6R)-1-{[5-bromo-2-(2H-1,2,3- triazol-2-yl)...)
Affinity DataIC50:  489nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316474(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50:  596nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316471(US9617246, 3 | US9617246, 48 | methyl 2-{[(3R,6R)-...)
Affinity DataIC50:  626nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316476(4-methyl-2-{[(3R,6R)-6-methyl-1- {[2-(2H-1,2,3-tri...)
Affinity DataIC50:  634nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316484(2-{[(3R,6R)-6-methyl-1-{[3-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50:  803nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin receptor type 2(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316509(2-({(3R,6R)-1-[(6-methoxy-2- pyrimidin-2-ylpyridin...)
Affinity DataIC50:  864nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316486(2-{[(3R,6R)-1-{[4-chloro-2-(2H-1,2,3- triazol-2-yl...)
Affinity DataIC50:  1.03E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316475(2-{[(3R,6R)-6-methyl-1-{[2-(2H- 1,2,3-triazol-2- y...)
Affinity DataIC50:  1.41E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetOrexin/Hypocretin receptor type 1(Homo sapiens (Human))
Merck Sharp & Dohme

US Patent
LigandPNGBDBM316488(2-{[(3R,6R)-6-methyl-1-{[4-methyl-2- (2H-1,2,3-tri...)
Affinity DataIC50:  1.50E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 74 total ) | Next | Last >>
Jump to: